Skip to main content

Table 1 Clinicopathological features stratified by QMSP

From: Impact of molecular surgical margin analysis on the prediction of pancreatic cancer recurrences after pancreaticoduodenectomy

Valiables All (n = 38) Molecular surgical margin analysis
Negative (n = 21) Positive (n = 17) p value
Age, years Median (range) 66 (36–86) 64 (36–86 72 (49–82) 0.735
Sex, n (%) Female 13 (34.2) 7 (33.3) 6 (35.3) 1
Male 25 (65.8) 14 (66.7) 11 (64.7)
Tumor size, cm Median (range) 2.3 (0.9–4.3) 2.5 (0.9–3.5) 2.1 (1.0–4.3) 0.401
Initial resectability, n (%) Resectable 16 6 10 0.133
Borderline resectable 15 11 4
Unresectable 7 4 3  
NAT, n (%) Yes 24 (63.2) 17 (81.0) 7 (41.2) 0.019
No 14 (36.8) 4 (19.0) 10 (58.8)
Radiation, n (%) Yes 3 (7.9) 3 (14.3) 0 (0) 0.238
No 35 (92.1) 18 (85.7) 17 (100)
CA19-9, U/ml Median (range) 51.5 (1–5790 51 (1–5790 53 (1–1020) 0.871
DUPAN-2, U/ml Median (range) 61.5 (25–1000) 47 (25–590) 120 (25–1000) 0.121
Pathological surgical margin, n (%) Positive 11 (28.9) 6 (28.6) 5 (29.4) 1
Negative 27 (71.1) 15 (71.4) 12 (70.6)
Pathological surgical margin, μm Median (range) 829 (0–4000) 1081 (0–4000) 372 (0–2648) 0.521
CY, n (%) Positive 3 (7.9) 1 (4.8) 2 (11.8) 0.577
Negative 35 (92.1) 20 (95.2) 15 (88.2)
n, n (%) Positive 6 (15.8) 5 (23.8) 1 (5.9) 0.197
Negative 32 (84.2) 16 (76.2) 16 (94.1)
ly, n (%) Positive 23 (60.5) 12 (57.1) 11 (64.7) 0.744
Negative 15 (39.5) 9 (42.9) 6 (35.3)
v, n (%) Positive 16 (42.1) 7 (33.3) 9 (52.9) 0.324
Negative 22 (57.9) 14 (66.7) 8 (47.1)
s, n (%) Positive 29 (76.3) 16 (76.2) 13 (76.5) 1
Negative 9 (23.7) 5 (23.8) 4 (23.5)
rp, n (%) Positive 29 (76.3) 15 (71.4) 14 (82.4) 0.476
Negative 9 (23.7) 6 (28.6) 3 (17.6)
ch, n (%) Positive 12 (31.6) 6 (28.6) 6 (25.3) 0.734
Negative 26 (68.4) 15 (71.4) 11 (64.7)
du, n (%) Positive 15 (39.5) 7 (33.3) 8 (47.1) 0.509
Negative 23 (60.5) 14 (66.7) 9 (52.9)
pv, n (%) Positive 12 (31.6) 7 (33.3) 5 (29.4) 1
Negative 26 (68.4) 14 (66.7) 12 (70.6)
  1. Bold indicates P < 0.05
  2. NAT; neoadjuvant chemotherapy, CY; Peritoneal washing cytology, n; Lymph node metastasis, ly; Lymphatic invasion, v; Venous invasion, s; Serosal side of the anterior pancreatic invasion, rp; Retropancreatic tissue invasion, ch; Bile duct invasion, du; Duodenal invasion, pv; Portal vein system invasion